HUNAN ER-KANG PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.57 CNY | +1.18% |
|
+8.90% | -19.94% |
| Sales 2022 | 1.87B 258M 355M | Sales 2023 | 1.78B 246M 338M | Capitalization | 6.62B 915M 1.26B |
|---|---|---|---|---|---|
| Net income 2022 | 45M 6.22M 8.53M | Net income 2023 | -195M -26.94M -36.98M | EV / Sales 2022 | 3.66 x |
| Net cash position 2022 | 475M 65.67M 90.18M | Net cash position 2023 | 399M 55.15M 75.72M | EV / Sales 2023 | 3.49 x |
| P/E ratio 2022 |
160
x | P/E ratio 2023 |
-33.9
x | Employees | 1,497 |
| Yield 2022 |
0.85% | Yield 2023 |
-
| Free-Float | 26.5% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.18% | ||
| 1 week | +8.90% | ||
| Current month | -4.81% | ||
| 1 month | -4.81% | ||
| 3 months | -11.07% | ||
| 6 months | -24.41% | ||
| Current year | -19.94% |
1 week
2.35
2.59
1 month
2.252.72
Current year
2.083.28
1 year
2.083.93
3 years
2.085.50
5 years
2.087.26
10 years
2.0823.25
| Managers | Title | Age | Since |
|---|---|---|---|
Qingrong Sun
CEO | Chief Executive Officer | 38 | 19-11-13 |
Fang Wen Shuai
FOU | Founder | 58 | 03-10-21 |
Xun Zhao
DFI | Director of Finance/CFO | 36 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Wen Shuai
FOU | Founder | 58 | 03-10-21 |
Li Cheng Zhang
BRD | Director/Board Member | 45 | 05-09-30 |
Hai Ming Yang
CTO | Chief Tech/Sci/R&D Officer | 54 | 06-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 2.57 | +1.18% | 24,929,100 |
| 24-04-29 | 2.54 | +3.67% | 25,864,800 |
| 24-04-26 | 2.45 | +1.24% | 18,996,500 |
| 24-04-25 | 2.42 | +1.26% | 18,367,000 |
| 24-04-24 | 2.39 | -0.42% | 13,495,500 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
HUNAN ER-KANG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and sales of pharmaceutical excipients, finished drugs and bulk drugs. The Companyâs pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-17
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -19.94% | 732M | |
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B |
- Stock Market
- Equities
- 300267 Stock
